Trial · NCT00564876
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
NCT00564876, Phase 2, Terminated, Duke University; results first posted 2013-03-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer. Trials, record NCT00564876. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00564876
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
- NCT number
- NCT00564876
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Dasatinib
- First posted
- 2007-11-28
- Last updated
- 2015-02-23
- Results first posted
- 2013-03-08
- Limitations and caveats
- Limitations for this trial were the trial was stopped due to poor enrollment.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | First progression and survival every 3 months for 2 years, then every 6 months until 5 years, then yearly. | Response rate (radiologic and pathologic) in Stage IB and II to neoadjuvant dasatinib |
| Secondary | Safety and Tolerability of Neoadjuvant Dasatinib | Screening / Baseline; Neoadjuvant dasatinib Cycle 1 Day 1 and Day 22 | Determine the safety and tolerability of neoadjuvant dasatinib in early stage NSCLC. |
| Secondary | Gene Expression Profile Activation of Src Pathways | Baseline and after 3 weeks of dasatinib therapy at the time of definitive surgical resection. | Determine whether gene expression profile activation of Src pathways is correlated with anti-tumor activity of dasatinib in early stage NSCLC. |
| Secondary | Safety and Tolerability of Adjuvant Dasatinib | Duration of adjuvant treatment plus 30 days. | Determine the safety and tolerability of adjuvant dasatinib in early stage NSCLC. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | First progression and survival every 3 months for 2 years, then every 6 months until 5 years, then yearly. | |||
| SECONDARY | Safety and Tolerability of Neoadjuvant Dasatinib | Screening / Baseline; Neoadjuvant dasatinib Cycle 1 Day 1 and Day 22 | Due to insufficient accrual, data analysis was not performed. | ||
| SECONDARY | Gene Expression Profile Activation of Src Pathways | Baseline and after 3 weeks of dasatinib therapy at the time of definitive surgical resection. | Due to insufficient accrual, data analysis was not performed. | ||
| SECONDARY | Safety and Tolerability of Adjuvant Dasatinib | Duration of adjuvant treatment plus 30 days. | Due to insufficient accrual, data analysis was not performed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Neoadjuvant Dasatinib | 2 | |
| Overall Study | COMPLETED | Neoadjuvant Dasatinib | 2 | |
| Overall Study | NOT COMPLETED | Neoadjuvant Dasatinib | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Neoadjuvant Dasatinib | ||
| Total, other adverse events | Neoadjuvant Dasatinib | 0 | 2 |
| Total, serious adverse events | Neoadjuvant Dasatinib | 0 | 2 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00564876
GET https://conductscience.org/api/trials/v1/NCT00564876/registered